Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 13/20 | 0.57 |
| ▸ | HRH1 | P35367 | 10/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 10/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4965938 | 0.87 | CCR3 (0.71) | CCR3HRH1KCNH2KDM4EALDH1A1 | |
| SCHEMBL4965148 | 0.86 | HRH1 (0.79) | CCR3HRH1KCNH2 | |
| SCHEMBL4967350 | 0.81 | HRH1 (0.59) | CCR3HRH1KCNH2MAPTOPRK1 | |
| SCHEMBL4968615 | 0.75 | HRH1 (0.78) | CCR3HRH1KCNH2 | |
| SCHEMBL25787103 | 0.75 | SMN1; SMN2 (0.58) | CCR3KDM4EALDH1A1SMN1; SMN2OPRK1 | |
| SCHEMBL6507440 | 0.74 | ATM (0.57) | MAPTALDH1A1SMN1; SMN2MAPK1ATM | |
| SCHEMBL242325 | 0.74 | ATM (0.57) | MAPTALDH1A1SMN1; SMN2MAPK1ATM | |
| SCHEMBL6501171 | 0.73 | ATM (0.56) | MAPTALDH1A1SMN1; SMN2MAPK1ATM | |
| SCHEMBL4965723 | 0.73 | CCR3 (0.57) | CCR3HRH1KCNH2MAPT | |
| SCHEMBL4967633 | 0.73 | HRH1 (1.00) | CCR3HRH1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1625114-B1 | Piperidine derivatives for the the treatment of chemokine or H1 mediated diseases | ASTRAZENECA AB (SE) | 2008-08-27 | — | — | EP | disclosed |